Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Assoc Physicians India ; 70(2): 11-12, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35436820

RESUMEN

COVID 19 pandemic has put a massive strain on healthcare all over the world. Every day new data is getting released and various complications are being reported in patients of COVID 19 Pneumonia. One such complication is pneumothorax and pneumomediastinum. Both these conditions can lead to an increase in mortality and morbidity in patients with COVID 19 pneumonia. We studied 476 patients of COVID 19 pneumonia at our hospital, out of which 18 (3.78%) had developed pneumothorax and/or pneumomediastinum. While most of these patients were on some form of positive pressure ventilation (invasive/non-invasive), some of them had a HRCT Chest suggestive of either air trapping and/or cyst formation. Three patients had developed bilateral pneumothorax while on non-invasive ventilator. Nine of the 18 patients expired and nine were discharged.Through this article, we would like to emphasize that an acute deterioration in hypoxemia in a COVID-19 patient could indicate a pneumothorax. Pneumothorax as well as pulmonary thromboembolism are reported complications in COVID-19 and clinician vigilance is required during assessment of patients, as both share the common symptom of breathlessness and therefore can mimic each other.


Asunto(s)
COVID-19 , Enfisema Mediastínico , Neumotórax , COVID-19/complicaciones , Hospitales , Humanos , Enfisema Mediastínico/diagnóstico , Neumotórax/diagnóstico por imagen , Neumotórax/etiología , SARS-CoV-2
2.
J Assoc Physicians India ; 69(7): 11-12, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-34431278

RESUMEN

COVID 19 is one of the world's worst hit pandemics. WHO first learned of this new virus on 31 December 2019, following a report of cluster of cases of 'viral pneumonia' in Wuhan, China. Covid 19 causes systemic infection but it worst hits the lungs and can cause ARDS ( 5%). Bilateral lung fibrosis is a commonly observed sequela after severe Covid 19 infection. Covid 19 pneumonia also acts as a nidus for superadded bacterial and fungal infections. However we haven't come across fibrocavitation and fungus ball as post Covid 19 sequelae.brbrWe here present a case report of a patient who was diagnosed as ARDS due to SARS CoV2, was treated as per standard Covid 19 protocols, required NIV and discharged on home oxygen. The HRCT on discharge showed bilateral fibrosis. The follow up HRCT after 45 days of discharge showed evidence of Bilateral cavities with Fungus ball.


Asunto(s)
COVID-19 , Enfermedades Transmisibles , Micosis , Hongos , Humanos , SARS-CoV-2
3.
Respir Med ; 168: 105949, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32469706

RESUMEN

BACKGROUND: Cough is a common yet distressing symptom that results in significant health care costs from outpatient visits and related consultations. OBJECTIVE: The understanding of the pathobiology of cough in recent times has undergone an evolution with Cough hypersensitivity syndrome (CHS) being suggested in most cases of dry cough. However, in the case of productive cough, ancillary mechanisms including impaired Mucociliary clearance, in addition to hypermucosecretory bronchospastic conditions of Smoker's cough, asthma-COPD overlap, bronchiectasis, and allergic bronchopulmonary aspergillosis, need to be critically addressed while optimizing patient care with symptomatic therapy in outpatient settings of India. METHODS: In this review, evidence-based graded recommendations on use of antitussives - & protussives as a Position Paper were developed based on the Level and Quality of Scientific evidence as per Agency for Health Care and Quality (AHRQ) criteria listing and Expert opinions offered by a multidisciplinary EMA panel in India. RESULTS: Management of acute or chronic cough involves addressing common issues of environmental exposures and patient concerns before instituting supportive therapy with antitussives or bronchodilatory cough formulations containing mucoactives, anti-inflammatory, or short-acting beta-2 agonist agents. CONCLUSION: The analyses provides a real world approach to the management of acute or chronic cough in various clinical conditions with pro- or antitussive agents while avoiding their misuse in empirical settings.


Asunto(s)
Antitusígenos/uso terapéutico , Tos/tratamiento farmacológico , Tos/etiología , Aspergilosis Broncopulmonar Alérgica/complicaciones , Asma/complicaciones , Bronquiectasia/complicaciones , Broncodilatadores/uso terapéutico , Tos/diagnóstico , Tos/economía , Medicina Basada en la Evidencia , Expectorantes/uso terapéutico , Directrices para la Planificación en Salud , Humanos , India , Errores de Medicación/prevención & control , Depuración Mucociliar , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Fumar/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...